Pharma companies have agreed to lower prices and invest in the U.S. in exchange for avoiding tariffs and benefits like faster ...

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as ...

The White House is set to announce drug pricing deals with pharmaceutical giants Novartis and Roche Holding as soon as Friday ...

FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain ...

Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and ...

Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

The Centers for Medicare & Medicaid Services (CMS) finalized the 2026 Outpatient Prospective Payment System (OPPS) rule with a wide range of policy updates that extend beyond core payment changes. A ...

Continued Investment in Pipeline and Acquired Assets in 2026 to Fuel Long-Term GrowthReaffirms Full-Year 2025 Adjusted(1) Diluted EPS Guidance(2) and Revises Full-Year 2025 Revenue Guidance(2) to ...

Some businesses have figured out how to take advantage of an expanded government presence in their boardrooms.

Oral GnRH antagonists like Myfembree, Yselty, and Oriahnn now lead uterine fibroid treatment, offering high efficacy in ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.